Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215715 · ClinicalTrials.gov registry record
US Benchmarking Clinical Study
A clinical trial of Cardiac Amyloidosis and Left Ventricular Hypertrophy, sponsored by eMyosound SAS.
- Recruiting
- Registry status
- 150
- Enrollment target
- 3
- Study locations
NCT07215715 is a study of Cardiac Amyloidosis and Left Ventricular Hypertrophy that is actively recruiting participants, run by eMyosound SAS. The registered enrollment target is 150 participants, below the 936-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT07215715, a study of Cardiac Amyloidosis and Left Ventricular Hypertrophy, is actively recruiting participants, sponsored by eMyosound SAS.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failure and left ventricular hypertrophy, with or without transthyretin amyloidosis with cardiomyopathy (ATTR-CM), and in control subjects without heart failure or cardiomyopathy. The main question it aims to answer is: • Can SWV be used to measure myocardial and liver stiffness in the study's target populations? Researchers will compare patients with ATTR-CM, patients without ATTR-CM, and a control group to determine the distributions of SWV in each population. Participants will: * Have a standard cardiology assessment, including a physical exam, blood work, and an echocardiogram. * Undergo an investigational assessment with the eMyosound LYRA device to measure SWV in their myocardium and liver. * Have the investigational assessment repeated by a second observer to assess measurement reliability.
Conditions Studied
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2026-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07215715
The ClinicalTrials.gov registry entry for NCT07215715 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (84% lower). The listed sponsor is eMyosound SAS, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Cardiac Amyloidosis appearing as the primary indexed condition, and to 0 interventions.
NCT07215715 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07215715 about?
NCT07215715 is a clinical study titled "US Benchmarking Clinical Study". The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failure and left ventricular hypertrophy, with or without transthyretin amyloidosis with cardiomyopathy (ATTR-CM), and in control subjects without...
What is the current status of trial NCT07215715?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2025-09-16. Estimated completion is 2026-07.
What conditions does trial NCT07215715 study?
This clinical trial studies the following conditions: Cardiac Amyloidosis, Left Ventricular Hypertrophy, HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy).
Who is sponsoring clinical trial NCT07215715?
This trial is sponsored by eMyosound SAS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215715 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study
RECRUITING · NA
-
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
RECRUITING
-
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
RECRUITING
-
Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis
RECRUITING · Phase 3
-
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.